Medicine Press release



Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning
May 09, 2024 09:41 JST
Fujitsu today announced the development of explainable AI technology that automatically draws on data in multiple formats, including text, images, and numerical data, to create knowledge graphs that will help users to more easily draw meaning from large-scale data sets with high accuracy for areas including medicine.
More info..


Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
May 02, 2024 10:00 JST
Mainboard listed Q&M Dental Group (Singapore) Limited ("Q&M" or "the Company" and together with its subsidiaries, the "Group") is proud to announce its integration of Align Technology's ("Align") iTero Lumina(TM) Intraoral Scanner in Singapore.
More info..


New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Apr 30, 2024 17:00 JST
BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.
More info..


New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Apr 30, 2024 17:00 JST
BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.
More info..


Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 09:53 JST
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.
More info..


Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 15:17 JST
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.
More info..


Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 10, 2024 12:36 JST
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a leader in IT, network and AI technologies, announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
More info..


Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 10, 2024 12:36 JST
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a leader in IT, network and AI technologies, announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
More info..


NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
Apr 08, 2024 12:45 JST
NEC Corporation (TSE: 6701) has released a white paper, "Towards the realization of AI drug development: Comprehensive process workflow for the commercial use of personalized cancer vaccines".
More info..


French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Apr 03, 2024 15:24 JST
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX").
More info..